KPRX - KIORA PHARMACEUTICALS INC
IEX Last Trade
3.2
0 0%
Share volume: 0
Last Updated: Fri 27 Dec 2024 04:05:54 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.90%
PREVIOUS CLOSE
CHG
CHG%
$3.20
0.00
0.00%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
1.82%
1 Month
-6.16%
3 Months
-2.33%
6 Months
-19.28%
1 Year
-33.53%
2 Year
-84.81%
Key data
Stock price
$3.20
DAY RANGE
$3.20 - $3.55
52 WEEK RANGE
$3.25 - $8.98
52 WEEK CHANGE
-$28.72
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Brian M. Strem
Region: US
Website: kiorapharma.com
Employees: 10
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: kiorapharma.com
Employees: 10
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Kiora Pharmaceuticals, Inc. develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.
Recent news